Compare SHOO & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHOO | LIVN |
|---|---|---|
| Founded | 1990 | 1987 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.5B |
| IPO Year | 1996 | 2015 |
| Metric | SHOO | LIVN |
|---|---|---|
| Price | $40.70 | $79.71 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 7 |
| Target Price | $42.14 | ★ $72.43 |
| AVG Volume (30 Days) | ★ 883.9K | 502.7K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.27% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.38 | ★ 2.33 |
| Revenue | ★ $2,534,109,000.00 | N/A |
| Revenue This Year | $12.39 | $9.79 |
| Revenue Next Year | $5.90 | $6.63 |
| P/E Ratio | ★ $29.32 | $34.11 |
| Revenue Growth | ★ 11.00 | N/A |
| 52 Week Low | $30.70 | $48.82 |
| 52 Week High | $49.70 | $85.76 |
| Indicator | SHOO | LIVN |
|---|---|---|
| Relative Strength Index (RSI) | 41.70 | 52.28 |
| Support Level | $41.79 | $61.63 |
| Resistance Level | $44.62 | $82.39 |
| Average True Range (ATR) | 1.26 | 2.11 |
| MACD | -0.22 | -0.12 |
| Stochastic Oscillator | 20.52 | 54.63 |
Steven Madden Ltd and its subsidiaries design, source, and market branded and private label footwear, accessories, and apparel. Its offerings include contemporary styles and core products, known for design creativity, trend-right offerings, high quality, and accessible price points. It operates through four segments: Wholesale Footwear, which generates maximum revenue and sells footwear globally; Wholesale Accessories/Apparel, which sells handbags and apparel through wholesale channels; Direct-to-Consumer, which sells footwear, handbags, apparel, and accessories through stores, outlets, e-commerce, and concessions; and Licensing, which licenses Steve Madden, Betsey Johnson, and Kurt Geiger trademarks, with the Company generating the majority of its revenue from the USA.
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.